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Intestinal drug absorption following oral administration can be influenced by regional 
conditions (absorbing surface area, bacterial flora, motility, pH, mucus thickness) and food 
intake, all of which affect drug solubility and permeability. Therefore, it is crucial to assess 
the impact of these conditions on the drugability of drugs and formulations. In this study, the 
ability of the liposome-based mucus-PVPA in vitro permeability model to handle relevant 
intestinal pH conditions was evaluated, together with the investigation on the pH-dependent 
solubility and permeability profiles of five model drugs. This study additionally evaluated the 
impact of all commercially available versions of the fasted and fed state simulated intestinal 
fluids (SIFs) on the integrity of the barriers, and the permeabilities of one hydrophilic and one 
lipophilic compound were examined under these conditions. The model was found to be well-
functioning in all tested pH conditions, and a pH-dependent trend was found for both 
solubility and permeability profiles for acidic and basic compounds, according to their degree 
of ionisation. Moreover, the mucus layer and its pH-dependent viscosity particularly 
influenced the permeation of more lipophilic compounds. The PVPA barriers primarily 
maintained their functionality in the presence of the fed state SIFs, and the permeability of the 
two tested compounds showed to be influenced by their hydrophilicity/lipophilicity, their 
degree of interaction with mucus and by the bile salts and phospholipids content in the SIFs. 
Overall, the obtained results highlight the relevance of studying the effect that pH, mucus and 
SIFs have on intestinal drug absorption, and suggest the suitability of the mucus-PVPA model 
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The small intestine forms the largest part of the gastrointestinal (GI) tract promoting the 
absorption of orally administered drugs (Billat et al., 2017). Its three segments (namely, 
duodenum, jejunum and ileum) are characterized by differences in length, absorbing surface 
area, bacterial flora, motility, pH and mucus thickness (Billat et al., 2017). The different 
regional characteristics can influence the solubility and permeability of drugs, and thereby 
their absorption after oral administration. For instance, the changes in pH through the length 
of the GI tract can influence the ionisation of the drugs and thus their intestinal absorption, as 
suggested by the pH partition hypothesis (Shore et al., 1957). Changes in pH can also affect 
the hydrophilic mucus layer, which lines, lubricates and protects the GI tract. This layer is the 
first barrier that drugs need to overcome in order to explicate their effect (Johansson et al., 
2013), and changes in pH can affect its structure and rheology, consequently impacting the 
diffusion properties of the drugs through it (Cao et al., 1999; Lieleg et al., 2010). 
In addition to the regional physiological changes in the GI tract, the characteristics and 
composition of the intestinal fluids vary widely according to the pre- or post- prandial state 
(Clarysse et al., 2009; Riethorst et al., 2016; Riethorst et al., 2018). In this regard, it has been 
demonstrated that bile salts and phospholipids in the human intestinal fluids can affect drug 
solubilisation, and thus influence permeability through the intestinal walls (Riethorst et al., 
2018). These regional and nutritional differences can also have an effect on drug absorption in 
a different manner according to the intrinsic characteristics of the drug in consideration and to 
its formulation features (Augustijns et al., 2014). A conspicuous effort has thus been put into 
simulating the human intestinal fluids, and as a result different versions of fasted and fed state 
simulated intestinal fluids (FaSSIF and FeSSIF) have been proposed (Galia et al., 1998; 
Jantratid et al., 2008). 
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Since all these variables can affect the absorption of drugs and formulations, understanding 
their impact is crucial, especially as oral drug administration is still regarded as the leading 
route for drug delivery due to its accessibility, great patient compliance and cost-effectiveness 
(Berben et al., 2018a). To assess the impact of these variables on drugability (i.e. the ability of 
a drug to be used as a satisfactory candidate for oral administration) while avoiding ethical, 
time- and cost-consuming issues related to human and animal testing, numerous in vitro 
permeability screening models have been proposed (Caco-2 model, Artusson et al., 2001; 
PAMPA model, Kansy et al., 1998; PVPA model, Flaten et al., 2006b; Permeapad™, di 
Cagno et al., 2015; AMI-system, Berben et al., 2018b ). Studies combining different in vitro 
permeability models with simulated intestinal fluids (SIFs) have been carried out by several 
research groups, and a special focus has been put on the impact that SIF-driven drug 
solubilisation and permeation have on drug absorption (Berben et al., 2018b; Bibi et al., 2015; 
Fischer et al., 2012; Naderkhani et al., 2015). Other studies have focused on the impact that 
pH variations in the intestine have on drug solubility and permeability, and on the interplay 
that occurs between the two (Sieger et al., 2017). The effect of the mucus layer on the 
permeability of drugs and formulations has been investigated both with respect to their 
diffusion through this layer alone (Fabiano et al., 2017; Shaw et al., 2005), as well as through 
in vitro barriers in the presence of this hydrophilic layer (Falavigna et al., 2018; Keemink and 
Bergström, 2018; Stappaerts et al., 2018). 
In the present study, we aimed to combine all the investigations discussed above. In 
particular, we utilised our previously developed modification of the PVPA (Phospholipid 
Vesicle-Based Permeation Assay) barrier comprising mucus (namely, mucus-PVPA, 
Falavigna et al., 2018) as a model for the intestinal membrane to move one step further 
towards closer mimicking the in vivo environment by studying the impact that pH and 
fasted/fed state SIFs have on drug permeability, as well as their interplay with mucus. The 
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integrity of these liposome-based barriers was assessed in terms of permeability of a 
hydrophilic fluorescent marker and of the electrical resistance across the barriers at different 
pH and in the presence of different fasted and fed state SIFs. Subsequently, the solubility and 
permeability profiles of five model acidic/basic compounds were evaluated together with the 
investigation on the rheological behaviour of mucus at different pH conditions. Lastly, the 
permeability of a hydrophilic marker and a lipophilic BCS class II drug was examined in the 
presence of all commercially available versions of fasted and fed state SIFs. 
Overall, the results collected in this study highlight the importance of assessing the impact 
that pH, mucus and fasted/fed SIFs have on drug permeability, and suggest the mucus-PVPA 
to be a promising tool for such purpose. 
 




Ammonium molybdate, calcein (CAL), chloroform, ethanol (96%, v/v), Fiske-Subbarow 
reducer, glacial acetic acid (≥99.8%), hydrochloric acid, ibuprofen (IBP), indomethacin 
(IND), maleic acid, methanol CHROMASOLV®, metoprolol (MTP), metronidazole (MTR), 
mucin from porcine stomach type III (bound sialic acid 0.5-1.5%, partially purified), 
naproxen (NPR), phosphorus standard solution, potassium phosphate monobasic, sodium 
chloride, sodium hydroxide, sodium phosphate dibasic dodecahydrate, sodium phosphate 
monobasic monohydrate and Triton X-100 were products of Sigma-Aldrich Chemie GmbH 
(Steinheim, Germany). E80 lipoid egg-phospholipids (80% phosphatidylcholine) were 
obtained from Lipoid GmbH (Ludwigshafen, Germany). Acetonitrile for HPLC (gradient 
grade) was a product of VWR chemicals (Fontenay-sous-Bois, France) and sulphuric acid 
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was purchased from May&Baker LTD (Dagenham, England). Hydrogen peroxide 30% and 
Titriplex® III were obtained from Merck KGaA (Darmstadt, Germany). 
FaSSIF/FeSSIF/FaSSGF, FaSSIF-V2 and FeSSIF-V2 powders were purchased from 
biorelevant.com (Croydon, UK). All chemicals employed were of analytical grade. 
For the preparation of the PVPA barriers, nucleopore track-etch membrane filters (0.4 and 0.8 
µm pore size) were purchased from Whatman (part of GE Healthcare, Oslo, Norway) and the 
nitrocellulose membrane filters (0.65 µm DAWP) were obtained from Millipore (Billerica, 
Massachusetts, USA). Transwell filter inserts and plates (d = 6.5 mm) were products of 
Corning Inc. (Corning, New York, USA). 
 
2.2. Drugs pH-dependent solubility studies 
 
The solubility of different drugs (IBP, IND, MTP, MTR, NPR) was investigated at pH 5.5, 
6.2 and 7.4 at room temperature (23-25 °C), following the method described by Berthelsen et 
al., (2014). 
Briefly, phosphate buffer saline (PBS) was prepared in order to obtain three buffers with 
different final pH (5.5, 6.2 and 7.4). 15 mg of drug were dispersed in 15 mL of PBS in a 15 
mL tube, and left to rotate on a Labinco test-tube rotor (Breda, The Netherlands) for a total of 
24 hours. After 1, 4 and 24 hours, the tubes were centrifuged for 10 minutes at 4500 rpm on a 
Biofuge Stratos thermostated centrifuge (Heraeus Instruments GmbH, Hanau, Germany), 
where the temperature was kept between 23 and 25 °C to avoid sample heating and further 
drug solubilisation. 1 mL of the supernatant solution was further centrifuged for 10 minutes at 
13000 rpm on a Biofuge pico centrifuge (Heraeus Instruments GmbH, Hanau, Germany), in 
order to provide an additional separation of the possible undissolved drug, thus making sure 
that the amount of drug quantified at the end of the experiment would only be the fraction 
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dissolved in the aqueous media. The supernatant was diluted and the amount of drug 
dissolved was quantified spectrophotometrically on SpectraMax 190 Microplate reader 
(Molecular Devices Corporation, California, USA). The 15 mL tubes were vortexed and put 
back on the rotor. For each drug and each pH, 2 samples were prepared and analysed to assess 
changes in solubility. 
IBP, IND, MTP, MTR and NPR were quantified spectrophotometrically on SpectraMax 190 
Microplate reader (Molecular Devices Corporation, California, USA) at wavelengths of 220, 
254, 274, 320 and 270 nm, respectively. 
 
2.3. PVPA barrier preparation 
 
The PVPA barriers were prepared according to the method previously described by 
Naderkhani et al. (2014a). Briefly, egg-phospholipids (E80) liposomes were obtained by the 
film hydration technique and extruded to obtain liposomes with two different size populations 
by means of 0.8 and 0.4 µm pore size filters. The liposomes were then deposited by 
centrifugation on top of cellulose ester filters (0.65 µm pore size), followed by a freeze-thaw 
cycle to immobilize and fuse the liposomes to the filter support. 
 
2.3.1. Mucus-PVPA barrier preparation 
 
To assess the impact of the mucus layer on drug permeability, 50 µL of mucin dispersion 
were added on top of the PVPA barriers according to the method previously described by us 
(Falavigna et al., 2018). Briefly, mucin from porcine stomach type III was hydrated with PBS 
pH 7.4 in order to achieve a final concentration of 10 mg/mL or 40 mg/mL. The dispersion 
was directly pipetted on top of the PVPA barriers and was left to incubate for 5 minutes prior 
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to the addition of the drug/marker solution. When the impact of different pH on drug 
permeability was investigated, the mucin dispersion was adjusted to the investigated pH with 
the use of HCl or NaOH solutions before its addition on top of the barriers. 
 
2.3.2. Mucus rheology 
 
Rheology measurements of the mucus prepared with different concentrations of mucin (10 
and 40 mg/mL) as well as at different pH (5.5, 6.2 and 7.4) were performed on a Discovery 
HR-2 hybrid rheometer (TA instruments, New Castle, USA) equipped with a Peltier plate 
environmental system, a cross hatched 40 mm parallel plate geometry, and a cross hatched 
lower plate. The sample was placed on the lower plate, the geometry was lowered to the 
measuring gap of 1000 µm, and the system was let equilibrate for 180 seconds at 25 °C (the 
same temperature at which the permeability experiments were performed). The viscosity of 
the different mucus simulating dispersions and the stress applied were measured using a 
logarithmic flow sweep with steady state sensing, where the shear rate was increased 
incrementally with 30 points per decade from 2 to 200 1/s. For each mucin concentration and 
each pH, three samples were prepared and measured. 
 
2.4. Simulated intestinal fluids preparation 
 
To study the effect of simulated intestinal fluids (SIFs) on the integrity of the PVPA barriers 
and on drug permeability, fasted (Fa-) and fed (Fe-) state SIFs were prepared according to the 
standardised protocol provided by the supplier (biorelevant.com). In this study, two versions 
(V1 and V2) of the simulated intestinal powders were used. Briefly, FaSSIF/FeSSIF/FaSSGF 
(producing FaSSIF-V1 or FeSSIF-V1), FaSSIF-V2 or FeSSIF-V2 powder was dissolved in 
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the corresponding fasted (FaB-V1 or V2) or fed (FeB-V1 or V2) buffer. The compositions of 




2.5. In vitro permeability studies 
 
The (mucus-)PVPA barriers were used to study the permeability of different drugs/marker at 
room temperature (23-25 °C) following the procedure previously described (Falavigna et al., 
2018), in the presence and absence of a mucus layer at different pH conditions and using 
different dissolution media. When the experiment was carried out in the presence of mucus, 
50 µL of mucin dispersion were added on top of the PVPA barriers and let to incubate for 5 
minutes prior to the addition of the drug/marker in solution. After the drug/marker solution 
(100 µL) was added on top of the PVPA barriers/mucus layer, the inserts were placed in an 
acceptor compartment containing 600 µL of PBS pH 7.4, simulating the in vivo blood 
circulation. The inserts were moved to fresh acceptor compartments after 1, 2, 3, 3.5, 4, 4.5 
and 5 hours in order to maintain sink conditions. After 5 hours, the samples were collected 
from the acceptor compartment prior to their quantification, and the electrical resistances of 
the barriers were measured to examine the integrity of the barriers. 
IBP, MTP, MTR and NPR were spectrophotometrically quantified as described in 2.2. IND 
was quantified by HPLC-UV at a wavelength of 254 nm (retention time 3.05 min; injection 
volume: 20 µL) using a Waters X-select™ CSH ™ C18 (2.5 μm, 3.0 × 75 mm) XP column 
(guard cartridge: Waters X-select™ CSH ™ C18 3.5 μm, 3.0 × 20 mm) on a Waters e2795 
Separation Module connected to a Waters 2489 UV/Visible Detector (Waters, Milford, 
Massachusetts, USA). The flow rate was adjusted to 0.5 mL/min and the mobile phase 
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consisted of acetonitrile and MilliQ water with 0.1% glacial acetic acid (60:40, v/v). CAL was 
quantified spectrofluorometrically at excitation and emission wavelengths of 485 and 520 nm, 
respectively, using a POLARstar Galaxy fluorometer (Fluostar, BMG Labtechnologies, 
Offenburg, Germany). Validation parameters, LOD and LOQ for the quantification of all 
compounds can be found in the Supplementary Material. 
The apparent permeability coefficient (Papp) was calculated with the following equation, 













where dQ/dt expresses the slope at the steady-state conditions (nmol/s), A is the surface area 
of the barriers (cm2 ) and Cd represents the concentration of the drug/marker in the donor 
compartment (nmol/mL). 
To ensure sink conditions, the drug/marker concentrations added in the donor compartment 
were selected in order to achieve a value below the solubility limit (< 10% of the donor 
concentration) in the acceptor compartment (Flaten et al., 2006a, b). 
For each drug/marker in each condition, the permeability study was carried out at least in 
triplicate (6 PVPA barriers tested for each one of the three parallels). 
 
2.5.1. The effect of pH on barrier integrity and drug permeability 
 
To assess changes in Papp due to different pH conditions of the solution in the donor 
compartment, several drugs/marker (i.e. CAL, IBP, IND, MTP, MTR and NPR) were 
dissolved in PBS pH 5.5, 6.2 or 7.4. In the case of the permeability experiment in the presence 
of mucus, mucin 10 mg/mL was prepared according to the pH of the drug/marker solution. 
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In particular, as an increase in the permeability of the fluorescent marker CAL would indicate 
possible disruption of the barriers (Flaten et al., 2006b; Naderkhani et al., 2015), its 
permeability was quantified to investigate the impact of changes in pH on the integrity of the 
barriers. 
 
2.5.2. The effect of simulated intestinal media on barrier integrity and drug 
permeability 
 
To investigate the impact of the SIFs on the integrity of the barrier and on the permeability of 
drugs, CAL and IBP were dissolved in FaB, FeB, FeSSIF or FaSSIF (V1 and V2), and their 
Papp was evaluated in the presence and absence of mucus (mucin 10 mg/mL). The mucus layer 
was prepared in accordance with the pH of the media. 
As the Papp of CAL dissolved in the fasted media was exceeding the standard range (Flaten et 
al., 2006b), the influence of mucin 40 mg/mL on the permeability of CAL was investigated to 
examine its potential to act as a further protective layer for the PVPA barriers. 
Moreover, the same conditions studied by Fischer et al. (2012) were investigated in this study. 
Briefly, the PVPA barriers were incubated for 1 hour in FaB (V1 or V2) prior to the addition 
of the CAL solution in the fasted buffers/media (FaB, FaSSIF V1 and V2), and the 
permeability of CAL was quantified for a total of 4 hours following the procedure described 
in section 2.5. 
 
2.6. Phospholipid quantification 
 
The amount of phospholipids lost from the PVPA barriers in the presence of fasted and fed 
state buffers/media was quantified using the modified phosphorus assay (Bartlett, 1959), 
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following the method previously described by Naderkhani and colleagues (Naderkhani et al., 
2015). Briefly, the PVPA barriers were placed in an acceptor compartment containing 600 µL 
of PBS pH 7.4 and the donor compartment was loaded with FaB, FeB, FaSSIF or FeSSIF (V1 
and V2) (100 µL). The barriers were incubated for 5 hours. The incubations in PBS pH 7.4 
and 0.5 % Triton X-100 were used as negative and positive control, respectively. Samples (50 
µL) were withdrawn from the donor compartment after 5 hours, diluted with 50 µL of 
distilled water and treated following the phosphorus assay. Blanks (PBS pH 7.4, 0.5 % Triton 
X-100, FaB, FeB, FaSSIF, FeSSIF, V1 or V2) were treated in the same manner. Three PVPA 
barriers for each condition were tested. 
 
2.7. Statistical analysis 
 
The statistical evaluation of all results was carried out using GraphPad Prism 7.0 software. 
When significant difference between two sets of data was to be highlighted, student-t test was 
employed (p < 0.05). One-way ANOVA was used to compare three or more sets of data and 
the Bonferroni post hoc test was employed to detect significant differences (p < 0.05). 
 
3. Results and discussion 
 
3.1. The pH environment of the intestinal tract 
 
Drug solubility and permeability in the intestinal tract are regarded as the two major factors 
affecting oral drug absorption, especially with regards to poorly soluble compounds. As the 
pH environment of the intestine varies widely through its length (5.6-7.8, Bergström et al., 
2014), it is of key importance to investigate its effect on solubility and permeability. In order 
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to infer if a pH-dependent solubility/permeability trend could be observed for drugs with 
different physicochemical characteristics, we studied the impact that a shift in pH could have 
on the solubility and permeability of five different drugs. Moreover, as drug permeability was 
assessed both in the presence and absence of a mucus layer at pH 5.5, 6.2 and 7.4, the 
investigation on the integrity of the PVPA barriers and the rheological characterisation of 
mucus in such pH conditions were carried out. 
 
3.1.1. Barrier integrity and mucus characterization 
 
To guarantee the optimal functionality of the (mucus-)PVPA barriers, their integrity was 
investigated at pH 5.5, 6.2 and 7.4. CAL was chosen as a marker to detect changes in barrier 
integrity at the selected pH conditions both in the presence and absence of the mucus layer. 
Fig. 3a (shaded area) shows that no significant increase in CAL permeability was found 
compared to the reference value (0.06 * 10-6 cm/s; Flaten et al., 2006b; Flaten et al., 2008), 
suggesting that the investigated conditions did not cause any barrier impairment. The 
electrical resistance across the barriers was measured after 5 hours, and the results (data not 
shown) also indicated intact barriers (electrical resistance > 290 Ohm*cm2, Naderkhani et al., 
2015). 
 
Since drug permeability in the intestinal environment could be affected by the rheology of the 
mucus layer, and as it has been demonstrated that mucus can undergo a conformational 
change induced by a shift in pH (Lieleg et al., 2010), rheology measurements of the mucus 




As it can be observed in Fig.1, the general Newtonian behaviour of the mucus at pH 6.2 (10 
mg/mL) and 7.4 (10 and 40 mg/mL) confirmed previous findings regarding mucus rheology 
(Falavigna et al., 2018; Mackie et al., 2017). However, when decreasing the pH of the mucin 
hydration media to 5.5, a non-Newtonian (shear-thinning) behaviour was observed (Fig. 1), 
correlating with what other research groups have found in the in vivo mucus layer (Boegh et 
al., 2014; Lai et al., 2009). These findings show how the rheology of mucus could be affected 
by the change in environmental pH. In fact, Cao et al., (1999) have suggested that a sol-gel 
transition could result from a pH-induced conformational change when decreasing the pH 
from 6-7 to a more acidic one. Lieleg et al., (2010) have also proposed that, at lower pH, the 
mucus layer tends to generate a stronger barrier toward particle mobility compared to a 
neutral pH environment. With regards to mucus viscosity, Fig. 1 shows that a decrease in pH 
or an increase in mucin concentration, causes an increase in apparent viscosity, as previously 
observed in other studies (Cao et al., 1999; Park et al., 2007). 
The results obtained in this study prove that mucus can undergo relevant rheology changes, 
which should be carefully taken into account when assessing the behaviour of a drug in such 
environment. These considerations are especially relevant when investigating the diffusion of 





3.1.2. Drugs pH-solubility profiles 
 
The pH-dependent permeability profiles of five model drugs were evaluated using the mucus-
PVPA model. The selection of the drugs was carried out to cover both acidic (IBP, IND, 
MTR and NPR) and basic (MTP) compounds as well as compounds with different degree of 
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lipophilicity (Table 2). Since the pH-dependent solubility of a drug is important when 
investigating its ability to permeate the GI barrier, solubility studies of the five model drugs 




As it can be observed from Fig. 2 and Table 2, the equilibrium solubility of the investigated 
drugs at the different pH conditions was dependent on their acidity constant (pKa), the pH of 
the medium in which the drugs were solubilized and their intrinsic 
hydrophilicity/lipophilicity. In particular, for IBP, IND and NPR (acidic and lipophilic drugs 
with pKa ≈ 4 and LogP > 3), the solubility significantly increased (p < 0.05) from pH 5.5 to 
7.4, as their degree of ionization increases at pH higher than their isoelectric point. In the case 
of the basic drug MTP (pKa 9.56, LogP 1.88), a non-significant decrease in solubility was 
found when increasing the pH to 7.4. This finding is most likely related to the fact that the pH 
conditions at which the experiments have been performed were far below the isoelectric point 
of MTP, thus not significantly differentiating the solubilities at pH 5.5, 6.2 and 7.4. For MTR 
(pKa 2.62, LogP -0.02), a significant increase was only observed when comparing the 
solubility at pH 5.5 with the other two pH conditions. Again, this is most likely due to the fact 
that solubility changes are only observable when comparing pH closer to the isoelectric point. 
Moreover, the hydrophilicity/lipophilicity of the examined drugs highly influenced their 
solubility. The more hydrophilic compounds such as MTP and MTR were found to be more 






These findings are in accordance with previous pH-dependent investigations carried out both 
in vitro and in silico (Bergström et al., 2004; Shoghi et al., 2013; Völgyi et al., 2010; Varma 
et al., 2012). 
Nonetheless, it has to be noted that the solubility profiles are substance-specific and that not 
only the pH, but also the ionic strength and the buffer capacity of the environment simulating 
the intestinal media should be carefully considered (Bergström et al., 2014; Hamed et al., 
2016; Madsen et al., 2018). 
 
3.1.3. Drugs pH-permeability profiles 
 
The Papp of the same five model drugs was examined in the presence and absence of mucus 
layer at different pH conditions (5.5, 6.2 and 7.4) to investigate their possible pH-dependent 
permeability. 
In general, the permeability of the investigated compounds in the absence of the mucus layer 
was found to be highly affected by their degree of ionization (Fig. 3), in accordance with the 
pH partition hypothesis (Shore et al., 1957). It has previously been shown that an increase in 
the fraction of drug in its unionized form directly increases the permeability of the drug 
(Flaten et al., 2008; Shore et al., 1957). In particular, in our study it was found that, for the 
BCS class II acidic drugs IBP and NPR, the permeability significantly decreased (p < 0.05) 
with increasing pH of the donor compartment, as the ionized form became the predominant 
one. Correspondingly, the permeability of the BCS class I basic drug MTP exhibited an 
increase in Papp when the pH was increasing from 5.5 to 7.4. For the BCS class II IND, the 
decrease in Papp with increasing pH was less visible, probably due to the highly lipophilic 
nature of the compound, which can cause a retention of the drug into the barriers and thereby 
causing a low recovery at the end of the experiment (Naderkhani et al., 2015). With regards to 
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BCS class I MTR, no change in permeability was found at different pH conditions. This was 
most likely due to the fact that the pH conditions of the experiments were significantly above 
the isoelectric point for this acidic compound, in accordance with the solubility results 
discussed in section 3.1.2. Furthermore, it has to be noted that more lipophilic compounds 
such as IBP and NPR (LogP > 3) are able to permeate the lipophilic PVPA barriers to a higher 
degree compared to more hydrophilic ones such as MTP and MTR due to their intrinsic 
nature. 
The (mucus)-PVPA has previously shown to correlate well with in vivo data on the fraction 
absorbed in humans (Flaten et al., 2006b; Naderkhani et al., 2014b; Falavigna et al., 2018). 
Furthermore, satisfactory correlations were found between the results obtained in this study at 
the different pH conditions (7.4, 6.2 and 5.5) and data where drug permeability was assessed 
at comparable pH (6.83) using a mucus-comprising Caco-2 cell model (Fig.2S and 3S, 
Supplementary Material). Especially in the case of the (mucus)-PVPA data at pH 7.4, which 
was the pH closest to the one used in the Caco-2 cell experiments, R2 of 0.96 and 0.97 were 




As the intestinal walls are lined with a mucus layer that differs in pH according to the specific 
location (Lieleg et al., 2010), the permeability of the same compounds was tested in the 
presence of mucin 10 mg/mL to assess the impact of this additional layer at different pH 
conditions. With regards to mucus-drug interaction, it has to be noted that there are multiple 
mechanisms which could take place when different drugs are in contact with this layer. In 
particular, Olmsted and colleagues (Olmsted et al., 2001) suggested interaction filtering 
(depending on specific binding interactions, electrostatic and hydrophobic forces and 
hydrogen bonds) and size filtering as the two main driving forces for the diffusion of drugs 
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through the hydrophilic mucus layer. This emphasizes the fact that more lipophilic 
compounds might decrease their rate of diffusion through mucus to a higher extent compared 
to hydrophilic ones, and that their ionization might further be the driving force according to 
the pH environment (Khanvilkar et al., 2001; Shaw et al., 2005). 
When the hydrophilic mucus layer was added on top of the PVPA barriers, the permeability 
of the different drugs was generally decreased compared to its absence, and the pH effect was 
also less evident (Fig. 3). As the isoelectric point of mucin is estimated to be between 2 and 3 
(Lee et al., 2005), its ionization would increase with the increase in pH. When the same 
occurs for ionisable drugs, this could cause an electrostatic repulsion or interaction (according 
to the nature of the drug) that would translate into a decrease in the Papp of the drug (Shaw et 
al., 2005). 
Moreover, the lipophilicity of the drug might also affect its degree of interaction with the 
mucus layer. In particular, the permeability of the more lipophilic compounds IBP and NPR 
significantly decreased (p < 0.05) in the presence of the mucus layer compared to its absence 
in all tested pH conditions. 
Additionally, changes in the rheological characteristics of mucus, usually occurring with a 
shift in environmental pH, could affect the diffusion/permeability behaviour of drugs at 
different pH conditions. In fact, as it can be observed in Fig. 3 for IBP and NPR, the higher 
viscosity of the mucus at pH 5.5 (Fig. 1) could be a contributing factor to the greater decrease 
in permeability compared to the results at pH 6.2 and 7.4. The findings obtained in this study 
highlight how the inclusion of the mucus layer is of key importance when investigating pH-
dependent permeability, and emphasize the mucus-PVPA model as a suitable tool to study 




The permeability-solubility interplay was studied by plotting the permeability and the 
solubility of the different drugs previously investigated against the pH in the absence of 
mucus (Fig. 4). A similar trend would be visible by plotting the results in the presence of the 
mucus layer. As it can be observed, for acidic drugs with pKa around 4 (IBP, NPR and IND; 
Fig. 4A, B, C) the permeability was higher at more acidic pH, whereas their solubility showed 
the opposite pH-dependent trend. On the other hand, a pH-driven variation in solubility and 
permeability was not noticeable for MTR (Fig. 4D), as expected from its physicochemical 
characteristics (Table 2). For the basic drug MTP (Fig. 4E), the tendency of higher 
permeability at decreasing degree of ionization was observed, but a significant decrease in 
solubility was not visible. 
The trends observed can be explained by the pH partition hypothesis, which highlights the 
fact that ionisable drugs tend to permeate lipidic membranes when in their undissociated form 
(Shore et al., 1957), whereas their solubility is higher when the dissociated form is the 
predominant one. Moreover, these findings are in agreement with previous investigations on 
the pH-dependent permeability-solubility interplay for ionisable compounds (Sieger et al., 
2017). 
Since previous findings have emphasized that the solubility-permeability trade-off should be 
carefully considered when aiming to design optimal formulations (Dahan and Miller 2012; 
Porat and Dahan 2018), it is essential to combine permeability and solubility in vitro tools to 
elucidate this interplay. The PVPA model used in this study, together with pH-dependent 
solubility experiments, proved the relevance of this kind of investigation and showed to be 







3.2. The intestinal media environment 
 
Together with the variations in environmental pH, the intestine is also characterized by 
intraluminal fluids that can vary in composition according to the fasted or fed state (Clarysse 
et al., 2009). 
In particular, bile salts and lecithin have shown to form colloidal structures which can provide 
the entrapment of drug molecules and their subsequent increased solubilisation, especially 
with regards to lipophilic drugs (Augustijns et al., 2014; Jantratid et al., 2008; Dahan and 
Miller, 2012). The fraction of the drug solubilised by these structures is not readily able to 
permeate the intestinal walls (Miller et al., 2011) and, for this reason, it is important to assess 
the impact that intestinal fluids have on drug permeation. The commercially available FaSSIF 
and FeSSIF have previously been proved to mimic the composition of the human intestinal 
fluids (Jantratid et al., 2008) and have been extensively used in the past decade in numerous 
solubility and permeability studies using artificial cell-free permeability models (Berben et 
al., 2018b; Bibi et al., 2015; Fischer et al., 2012; Naderkhani et al., 2015). Therefore, in this 
study we evaluated the impact that these SIFs have on the PVPA barriers, as well as on the 
permeability of different compounds. 
 
3.2.1. PVPA barriers in the presence of simulated intestinal media 
 
The PVPA barriers used in this study have previously been shown to be stable in the presence 
of FaSSIF V1 by another research group (Fischer et al., 2012). However, as the components 
in the different SIFs could potentially interact with the PVPA lipids and affect the integrity of 
the barriers, we wanted to investigate this further. For the first time, in this study the PVPA 
and mucus-PVPA barriers were evaluated in terms of their compatibility with both the fed and 
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fasted state SIFs (namely, FeSSIF and FaSSIF, V1 and 2, composition found in Table 1). To 
the best of our knowledge, this is the first attempt in studying the impact that all the 
commercially available media versions (version 1, V1; version 2, V2) have on the 
functionality of the PVPA barriers; we believe that this investigation is crucial in order to 
design the best intestinal-resembling in vitro permeability model. 
The permeability of the fluorescent marker CAL was used to evaluate if the addition of the 
fed or fasted state SIFs would induce changes in the integrity of the PVPA barriers. 
As previously mentioned, an increase in the reference calcein Papp value (0.06 * 10
-6 cm/s) and 
decrease in barrier electrical resistance (< 290 Ohm*cm2) would suggest a potential change in 
barrier integrity (Flaten et al., 2006b; Flaten et al., 2008; Naderkhani et al., 2015). 
As it can be observed in Fig. 5, with the fed state buffers/media (Fig. 5A) the permeability of 
CAL did not increase compared to the control (PBS pH 5.5, Fig. 5A shaded area), suggesting 
that their presence did not influence the functionality of the barriers, both in the presence and 
absence of the mucus layer. On the other hand, a general increase in Papp and decrease in 
electrical resistance was observed when experiments with CAL dissolved in the fasted state 
buffer/media were performed (Fig. 5B). However, permeability of CAL was lower in the 
presence of buffers compared to the fasted state media, suggesting that the components found 
in the media (namely sodium taurocholate, lecithin, glycerol monooleate and sodium oleate; 
Table 1) could be causing changes in the integrity of the barriers. 
The presence of mucin 10 mg/mL seemed to shield the barriers from the effect of FaSSIF V1, 
which was the medium causing the most significant change in CAL permeability. Therefore, 
to test if mucus with a higher mucin concentration would provide additional protection of the 
barriers, mucin 40 mg/mL was also tested. As it can be seen from Fig. 5B, in general this 
setup led to a decrease in CAL Papp, especially in the case of the fasted state media, suggesting 
a higher degree of protection from the more concentrated mucus layer. However, CAL 
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permeability was still significantly higher compared to the control and the electrical resistance 
measured in this condition was still below the optimal range (< 290 Ohm*cm2; Naderkhani et 
al., 2015). 
As mentioned above, Fischer and colleagues (Fischer et al., 2012) concluded that the integrity 
of the barriers appeared to be maintained in the presence of the fasted state medium (V1) 
since the results obtained using FaB and FaSSIF (V1) were not statistically different. In this 
study, PBS pH 7.4 was not included as control. The permeability experiments performed by 
Fisher and colleagues were carried out in a different manner compared to the present study. In 
particular, the barriers were hydrated for 1 hour in FaB V1 and the following permeability 
assay was 4 hours long. For this reason, we decided to investigate the permeability of CAL in 
these conditions. As it can be observed in Fig. 5B, a significant decrease in calcein Papp was 
found with the hydrated-barriers setup, especially with the V1 fasted state medium. These 
findings, together with the differences in surface area and donor volume, as well as lab-to-lab 
variations, could be the reasons for the differences between the results obtained in the current 
study and the ones from Fischer and colleagues (Fischer et al., 2012). 
Moreover, in previous studies performed in our research group (Naderkhani et al., 2015) a 
modification of the original PVPA model (namely, PVPAbiomimetic) was used to assess the 
impact of the fasted and fed state SIFs (V2). In accordance with our findings (Fig. 5), a higher 
CAL permeability and lower electrical resistance was observed in the presence of fasted state 
medium compared to the fed one (Naderkhani et al., 2015). However, with the PVPAbiomimetic 
the fasted medium (V2) was found to be much less aggressive to the barriers and thus more 
compatible with the model compared to the original PVPA (Naderkhani et al., 2015). The 
PVPAbiomimetic barriers have also shown to be more robust against the presence of co-solvents 
and tensides compared to the original PVPA (Naderkhani et al., 2014b), and are thus a good 
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alternative when permeability studies with conditions that might affect the original PVPA 




However, as the Papp of drugs/compounds can be differently affected according to their 
physicochemical characteristics, we wanted to investigate how the permeability of one more 
lipophilic compound would be affected in the presence of the SIFs. Therefore, the 
permeability of the BCS class II drug IBP was evaluated in the presence of fed and fasted 
state SIFs with and without the presence of the mucus layer, to see if the variation in the 
permeability of IBP would follow the same trend as the one of the hydrophilic marker CAL.  
As it can be seen in Fig. 5D, the permeability of IBP dissolved in the fasted state media in the 
absence of mucus significantly increased (p < 0.05) only in the case of FaSSIF V2, when 
compared to the one where the drug was dissolved in PBS pH 6.2 (Fig. 5D, shaded area). In 
the presence of the mucus layer, the corresponding buffer (FaB V2) also caused a significant 
increase in Papp. The electrical resistance across the PVPA barriers followed the trend seen in 
Fig. 5B, suggesting potential barrier impairment in the presence of the fasted state media. 
However, the permeability of this lipophilic compound was not affected by the presence of 
this media to the same extent as CAL, suggesting that the changes in the PVPA structure may 
be related to an increase in aqueous pores through the barriers and not to variations in their 
lipidic part. In fact, events that affect the structure of the PVPA barriers can cause an increase 
in aqueous pathways, resulting in a higher permeability especially for hydrophilic compounds 
(Flaten et al., 2006b). 
Fig. 5C shows the apparent permeability of IBP dissolved in the fed state (SIFs). In general, 
minor changes were found when comparing the Papp of the drug dissolved in PBS pH 5.5 
(control, shaded area) with the one in the fed state buffers/media in the presence and absence 
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of the mucus layer. These findings could be related to the different solubilisation that the drug 
can exhibit in these different environments, which again can translate into a change in 
permeability (Dahan and Miller 2012; Porat and Dahan 2018). Moreover, in all tested fed 
conditions, the Papp of IBP was found to be lower in the presence of mucus. On the contrary, 
as it can be seen in Fig. 5A, the permeability of the hydrophilic marker CAL did not 
significantly change between the presence and absence of mucus. In fact, the presence of the 
mucus layer can particularly hinder the diffusion of lipophilic drugs because of its hydrophilic 
nature and of the possible interaction of the drugs with its hydrophobic regions (Khanvilkar et 
al., 2001). These results were able to prove this concept, and stressed the necessity of a 
permeability in vitro model comprising mucus to properly assess its impact on oral drug 
absorption. 
As previously mentioned, lecithin and bile salts have shown to entrap drug molecules in 
vesicular structures, thus increasing drug solubilization and lowering the amount of free drug 
able to permeate through the intestinal walls (Augustijns et al., 2014; Miller et al., 2011). This 
effect should be particularly evident with the fed state media, where the concentration of the 
above-mentioned components is higher compared to the fasted state one. As a proof of this 
concept, Fig. 5C shows a significant decrease (p < 0.05) in permeability when comparing the 
Papp of IBP dissolved in FeB V2 with the one in FeSSIF V2, both in the presence and absence 
of mucus. In fact, the presence of sodium taurocholate, lecithin and other lipolysis products in 
FeSSIF V2 can provide the formation of micelles, otherwise not present in the fed state buffer 
(FeB V2), thus influencing drug solubilisation and permeability. A similar trend was found 
with FeB V1 and FeSSIF V1, but not to the same extent. This could be due to the different 
composition of the two media (Table 1), stressing the significant impact on drug permeation 
of the presence of FeSSIF V2, which has a higher bile salt-lecithin ratio and additional 
lipolysis products (sodium oleate and glycerol monooleate). Regarding this matter, it has been 
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previously shown that the complex composition of the fed intestinal fluids could contribute to 
larger colloidal vesicles (Riethorst et al., 2016) and therefore affect drug absorption to a 
higher extent. Moreover, according to the bile salt-lecithin ratio, the vesicles could change in 
dimension and tend either to a bilayered structure or to the one of mixed micelles, as 
previously discussed (Riethorst et al., 2018). The same trend was not observed for CAL (Fig. 
5A), emphasising that this study was able to highlight the fact that the FeSSIF composition 
did not affect the permeability of hydrophilic compounds in the same manner as lipophilic 
ones. 
In the presence of mucus, a significant decrease in IBP permeability (p < 0.05) was only 
found between FeB and FeSSIF V2 and not between FeB and FeSSIF V1 (Fig. 5C). This 
could again be traced back to the different composition of the two media, as well as to the 
potential interaction of the drug with the mucus. Moreover, the reduction in drug diffusion 
through native mucus has previously been found to be related to sodium taurocholate, 
competing with mucins in binding the drug diffusing through this layer (Legen and Kristl 
2001). 
 
All these considerations underline the impact that the different SIFs have on the permeation of 
different compounds through the PVPA barriers, but also on the diffusion of drugs through 
the mucus layer. These findings are especially relevant as the need of predictive in vitro 
models simulating the GI tract is further increasing (Berben et al., 2018a; Billat et al., 2017; 
Riethorst et al., 2018). 
 





To further investigate the mechanism behind the possible change in barrier integrity suggested 
by the increased CAL permeability discussed in section 3.2.1, the potential loss of lipids from 
the PVPA barriers in the donor compartment was investigated in the presence of the different 
SIFs. 
Fig. 6 shows how the loss of phospholipids in all tested conditions was significantly lower (p 
< 0.05) than the one caused by the presence of Triton X-100 0.5% (positive control), which is 
certainly causing barrier disintegration as proved by other authors (Fisher et al., 2011; 
Naderkhani et al., 2015). However, an increase in amount of phospholipids released from the 
barrier was observed with some of the SIFs compared to the presence of PBS pH 7.4 
(negative control). In particular, a significant increase in phospholipid loss compared to the 
negative control was observed in the presence of FaB V1, FaSSIF V1 and FaSSIF V2. 
Moreover, a significant difference in lipid loss was found between the buffer and the medium 
for the fasted state V2 and the fed state V1. 
These trends could explain part of the permeability results shown in Fig. 5B and add more 
information regarding the effects of the SIFs on the tightness of the PVPA barriers. In 
particular, a higher loss of lipids is suggested in the presence of the fasted state media, 
compared to the fed ones, in accordance with the results discussed in section 3.2.1. 
Moreover, the results in Fig. 6 are in the same range as the ones previously observed by 
Fischer and colleagues (Fischer et al., 2012). However, they did not compare the loss of 
phospholipids caused by the fasted state media with the one in the presence of PBS pH 7.4, 
therefore a negative control as the one discussed in our study was not accessible. 
Naderkhani et al. (2015) observed that a lower lipid loss was found with the PVPAbiomimetic 
barriers both in the presence of fasted and fed state media and of Triton X-100 0.5% 
compared to the original PVPA, highlighting the difference in barrier integrity and further 
supporting the permeability results discussed in section 3.2.1. 
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In the present study, the loss of phospholipids caused by the fed and fasted state buffer/media 
in the presence of the mucus layer was also investigated. However, the collection process of 
the samples from the donor compartment led to variations in the amount of mucus present in 
each sample. As mucus was prepared in phosphorus-containing buffer (PBS), the amount of 
phosphorus quantified in each sample varied according to the amount of mucus withdrawn 
from the donor compartment, thus leading to compromised sensitivity of the assay and the 




The different results observed using the FaSSIF and FeSSIF media could be ascribed to their 
different composition (Table 1), which is not only related to the different amounts of bile 
salts, lecithin and other lipolysis products, but also to their different buffer composition. In 
fact, as it can be observed in Fig. 5 and 6, in some cases the buffers themselves seemed to 
potentially affect the barrier integrity.  
Moreover, since it has been reported that the concentration of bile salts and lecithin in fasted 
state human intestinal fluid is much lower compared to the fed one (Clarysse et al., 2009) and 
since the SIFs have shown to mimic the human intestinal fluids (Jantratid et al., 2008), the 
resulting vesicular structures would be different according to FaSSIF or FeSSIF media, thus 
possibly affecting the PVPA barrier structure in a different manner. 
 
Overall, the results obtained suggest the PVPA barriers to be especially stable in the presence 
of the fed state media, whereas the ones found with the fasted state media suggest a certain 
potential of barrier impairment, and precautions should be taken when interpreting results 
obtained in presence this media. However, as the PVPAbiomimetic barriers have shown to be 
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more robust compared to the original ones (Naderkhani et al., 2014b), they could be the best 
model to use when fasted state SIFs have to be employed to assess drug permeability. 
Moreover, the findings discussed in section 3.2.1 highlight the fact that different media can 
result in a different impact on the PVPA barrier integrity as well as on the permeability of the 
model compounds. This emphasises the relevance of the investigation on both media and both 




In this study, the impact of regional and nutritional intestinal differences has been 
successfully investigated using the mucus-PVPA in vitro model. The pH-dependent drug 
permeability and solubility profiles showed trends in agreement with the pH partition 
hypothesis. An increase in mucus viscosity at lower pH conditions was also observed. 
Moreover, the impact of bile salts and phospholipids on drug permeation was evident, and the 
different SIFs showed to influence the permeability to various extents according to the 
hydrophilicity/lipophilicity of the drugs. Further, the presence of mucus particularly affected 
the permeability of the more lipophilic compounds. The results obtained in this work thus 
suggest the suitability of the mucus-PVPA model for investigations on the impact that pH and 
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Figure and table captions 
 
Fig. 1: Viscosity of mucus at different pH conditions (5.5, 6.2 and 7.4) and mucin 
concentrations (10 mg/mL and 40 mg/mL). 
 
 
Fig. 2: Solubility of metronidazole (MTR), metoprolol (MTP), naproxen (NPR), ibuprofen 
(IBP) and indomethacin (IND) at pH 5.5, 6.2 and 7.4. The results are indicated as mean ± SD 
(n = 6). Statistical significance (p < 0.05) was investigated with one-way ANOVA using the 
Bonferroni post hoc test. 
*statistically significant difference in solubility between pH 5.5 and 6.2/7.4. 
**statistically significant difference in solubility between pH 6.2 and 5.5/7.4. 
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Fig. 3: Apparent permeability (Papp) of metronidazole (MTR), metoprolol (MTP), naproxen 
(NPR), ibuprofen (IBP) and indomethacin (IND) in the presence and absence of mucus at pH 
5.5, 6.2 and 7.4. Papp of calcein (CAL) (shaded area) was quantified to investigate the integrity 
of the PVPA barriers at the chosen pH conditions. The results are indicated as mean ± SD (n 
= 18). Statistical significance (p < 0.05) was investigated with one-way ANOVA using the 
Bonferroni post hoc test. 
* statistically significant difference in Papp between different pH conditions in the absence of 
mucus. 
** statistically significant difference in Papp between different pH conditions in the presence 
of mucus. 
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Fig. 4: pH-dependent permeability-solubility interplay in the absence of mucus, depicted as 
apparent permeability (Papp, black dotted line) and solubility (grey dotted line) plots of 
ibuprofen (4A, IBP), naproxen (4B, NPR), indomethacin (4C, IND), metronidazole (4D, 




































































































































































































Fig. 5: Apparent permeability (Papp) of calcein (CAL; 5A, B) and ibuprofen (IBP; 5C, D), and 
electrical resistance of the PVPA barriers in the presence of fed (A, C) or fasted (B, D) state 
media (FeSSIF and FaSSIF, respectively) and corresponding buffers (FeB and FaB, 
respectively) for both versions 1 and 2 (V1, V2) in the presence and absence of mucus (10 
and 40 mg/mL) and with hydrated barriers. Papp and electrical resistance in the presence of 
PBS (pH 5.5 or 6.2) are used as controls (shaded area). The results are indicated as mean ± 
SD (n = 18). Statistical significance (p < 0.05) was investigated with one-way ANOVA using 
the Bonferroni post hoc test. 
+ statistically significant difference in Papp between the absence of mucus and the other 3 
conditions (mucus 10 mg/mL, mucus 40 mg/mL and hydrated barriers). 
* statistically significant difference in Papp between PBS and all other SIFs without mucus. 
** statistically significant difference in Papp between PBS and all other SIFs with mucus. 
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Fig. 6: Amount of phospholipids released to the donor compartment of the PVPA barriers 
after 5 hours of incubation with PBS pH 7.4, fasted (Fa-) and fed (Fe-) state buffers (FaB and 
FeB) and media (FaSSIF and FeSSIF) (both version V1 and V2) and Triton X-100 0.5%. The 
results are indicated as mean ± SD (n = 6). Statistical significance (p < 0.05) was investigated 
with one-way ANOVA using the Bonferroni post hoc test. 
* statistically significant difference in phospholipids loss compared to PBS pH 7.4. 
** statistically significant difference in phospholipids loss between the buffer and the media 
fluids. 
° statistically significant difference in phospholipids loss between the presence of Triton 0.5% 



















































































































Table 1: Composition of the fasted (Fa-) and fed (Fe-) state simulated intestinal blank buffers 
(FaB, FeB) and media (FaSSIF, FeSSIF) for both version 1 and version 2 (V1, V2), as 
described by the provider (biorelevant.com). 

















Sodium taurocholate (mM) - 3.00 - 3.00 - 15.00 - 10.00 
Lecithin (mM) - 0.75 - 0.20 - 3.75 - 2.00 
Glycerol monooleate (mM) - - - - - - - 5.00 
Sodium oleate (mM) - - - - - - - 0.80 
Maleic acid (mM) - - 19.10 19.10 - - 55.00 55.00 
Monobasic sodium phosphate 
monohydrate (mM) 
28.40 28.40 - - - - - - 
Sodium chloride (mM) 106 106 68.60 68.60 203 203 126 126 
Sodium hydroxide (mM) 8.70 8.70 101 101 101 101 82.00 82.00 
Glacial acetic acid (mM) - - - - 144 144 - - 
pH 6.5 6.5 6.5 6.5 5.0 5.0 5.8 5.8 
Osmolarity (mOsm/kg)  270  180  670  390 





Table 2: Chemical properties and solubility of calcein (CAL), ibuprofen (IBP), indomethacin 
(IND), metoprolol (MTP), metronidazole (MTR) and naproxen (NPR). 
 












IBP  4.45c 3.97d II 206.29 220 pH 5.5: 0.37 
pH 6.2: 1.06 
pH 7.4: 1.72 
IND  4.42c 4.27d II 357.79 254 pH 5.5: 0.03 
pH 6.2: 0.09 
pH 7.4: 0.71  
MTP  9.56c 1.88d I 267.36 274 pH 5.5: 1.01 
pH 6.2: 1.07 
pH 7.4: 0.99 
MTR  2.62e -0.02d I 171.15 320 pH 5.5: 1.02 
pH 6.2: 1.09 
pH 7.4: 1.07 
NPR  4.18c 3.18d II 230.26 270 pH 5.5: 0.15 
pH 6.2: 0.56 
pH 7.4: 1.37 
a: Flaten et al. 2006b 
b: Naderkhani et al. 2014a  
c: Avdeef 2003 
d: Benet et al. 2011 
e: Rediguieri et al. 2011 
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1. Quantification methods: drug permeated in the acceptor compartment 
The quantification of the amount of drug found in the acceptor compartment at the end of the 
permeability study was carried out with different quantification methods according to the 
specific compound. Previous studies by us have assessed the possibility of interference of lipids 
from the PVPA barrier in the quantification process, and have concluded that no lipids were 
found in the acceptor compartment (Flaten et al., 2007). UV-Vis spectrophotometry was 
sensitive enough for the quantification of IBP, MTP, MTR and NPR in the permeation studies, 
as the absorbance of each specific drug found in the acceptor compartment was inside the 
specific standard curve range and above the LOD and LOQ values (Table 1S). However, for 
the quantification on IND, HPLC-UV was needed since the absorbance in the acceptor 
compartment was not appreciable enough by the UV-Vis spectrophotometry quantification 
method. 
Table 1S: Parameters for the quantification of CAL, IBP, IND, MTP, MTR and NPR. 











5.5 0.10-2.20 0.9999 0.05 0.16 
6.2 0.10-2.20 0.9998 0.07 0.22 
7.4 0.02-2.20 0.9995 0.09 0.27 
 
IBP 
5.5 8.00-150.00 0.9994 6.70 20.29 
6.2 8.00-150.00 0.9994 6.70 20.29 
7.4 8.00-150.00 0.9999 2.99 9.06 
 
IND UV 
5.5 12.00-120.00 1 1.16 3.53 
6.2 12.00-120.00 1 0.82 2.49 
7.4 12.00-120.00 0.9992 7.86 23.82 
IND 
HPLC 
7.4 0.015-30.00 0.9998 0.56 1.70 
 
MTP 
5.5 1.00-30.00 0.9991 1.86 5.65 
6.2 1.00-30.00 0.9997 1.09 3.31 
7.4 1.00-30.00 0.9992 2.08 6.32 
 
MTR 
5.5 18.00-366.00 0.9997 14.00 42.42 
6.2 18.00-366.00 0.9999 8.75 26.50 
7.4 18.00-366.00 0.9998 6.50 19.70 
 
NPR 
5.5 50.00-250.00 0.9989 20.07 60.82 
6.2 50.00-250.00 0.9993 16.72 50.67 
7.4 50.00-250.00 0.9991 18.77 56.89 
 
For the validation of the HPLC-UV quantification method of IND, different parameters have 
been assessed. First, the evaluation of the right column type, mobile phase, time run and flow 
was carried out by injecting a standard IND solution (in PBS pH 7.4) and by monitoring the 
separation profile at 254 nm. The retention time of IND obtained with a Waters X-select™ CSH 
™ C18 (2.5 μm, 3.0 × 75 mm) XP column, a flow rate of 0.5 mL/min and a mobile phase of 
acetonitrile and MilliQ water with 0.1% glacial acetic acid (60:40, v/v) was found to be 3.05 
during a total run time of 5.5 minutes, while the retention time of the solvent front was found 
to be 1.07 minutes (Fig. 1S). The IND standard was injected at increasing concentrations (9 
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dilutions; 3 replicates for each dilution; 0.015-30 nmol/mL) in order to obtain a satisfactory 
calibration curve (R2 = 0.9998; LOD = 0.56 nmol/mL; LOQ = 1.70 nmol/mL). The retention 
capacity factor k was also evaluated and found to be acceptable (k = 1.87), together with the 
peak asymmetry factor (As = 1.22) and efficiency (N = 674). As both the standard IND solution 
and the samples obtained from the permeability study were only containing IND, the assessment 
of the selectivity and resolution was not possible. 
 
 
Fig. 1S: Chromatogram of IND standard. 
 
The spectrofluorometric determination of CAL was carried out following the method described 
by Flaten and colleagues (2006b). The excitation and emission wavelengths (485 and 520 nm, 
respectively) were chosen to accurately quantify the compound and to avoid a crosstalk between 
excitation and emission curves. A CAL standard solution (in PBS pH 7.4) was prepared at 
increasing concentrations (9 dilutions; 3 replicates for each dilution; 0.02-2.2 nmol/mL) in 
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2. Correlation between the (mucus)-PVPA and the Caco-2 model 
A correlation between permeabilities obtained using a mucus-comprising Caco-2 model 
(Berben et al., 2018b) with the permeability of four different drugs (IBP, IND, NPR, MTP) 
obtained using the PVPA barriers both in the absence and presence of mucus was carried out. 
The Caco-2 data used for these correlations was obtained from a study where mucus was added 
on top of Caco-2 cells prior to the addition of the drug in solution, which was dissolved in 
FaHIF (fasted state human intestinal fluids) at pH 6.83 (Berben et al., 2018b). The correlations 
are the following: 
 
Fig. 2S: Correlation between the Papp obtained using the Caco-2 model (data from: Berben et 
al., 2018b) and the PVPA model. 
 
Fig. 3S: Correlation between the Papp obtained using the Caco-2 model (data from: Berben et 
al., 2018b) and the mucus-PVPA model. 

































Correlation: Caco-2 vs. PVPA
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Correlation: Caco-2 vs. mucus-PVPA
m-PVPA pH 7.4 m-PVPA pH 6.2 m-PVPA pH 5.5
Linear (m-PVPA pH 7.4) Linear (m-PVPA pH 6.2) Linear (m-PVPA pH 5.5)
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As it can be observed in Fig. 2S and 3S, a satisfactory correlation for all pH conditions between 
the permeability data obtained using the Caco-2 model and the (mucus)-PVPA model has been 
obtained. This was especially evident in the case of (mucus)-PVPA data at pH 7.4, most likely 
due to the fact that the Caco-2 data was exclusively collected at pH 6.83. These correlations 
suggest the suitability of the model used in the current study for the investigation on drug 
permeation. 
 
 
